Skip to content

Efficacy of Topical Cysteamine in Nephropathic Cyctinosis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02766855
Enrollment
26
Registered
2016-05-10
Start date
2004-01-31
Completion date
2016-03-31
Last updated
2016-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephropathic Cyctinosis, Corneal Cystine Crystals

Keywords

cysteamine, nephropathic cystinosis, cystine crystals

Brief summary

The aim of this study is to evaluate the efficacy of topical cysteamine eye drops in the treatment of corneal cystine crystals deposits in patients with nephropathic cystinosis.

Detailed description

A total of 26 patients with nephropathic cystinosis were included in this prospective study. Patients were evaluated for improvement of corneal cysteine deposits crystals and photophobia following treatment with topical 0.55% cysteamine eye drops.

Interventions

Patients were asked to use topical cysteamine 0.55% eye drops every 2 hours while awake to both eyes.

Sponsors

The Eye Center and The Eye Foundation for Research in Ophthalmology
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
8 Months to 19 Years
Healthy volunteers
No

Inclusion criteria

* patients with confirmed diagnosis of nephropathic cystinosis * leucocyte cystine concentration level of more than 2.0 nmol half-cystine/ mg protein * clinical evidence of tissue deposition of cystine and tissue damage due to cystinosis

Exclusion criteria

* Allergy to cysteamine

Design outcomes

Primary

MeasureTime frameDescription
Number of participants with improvement of photophobia, corneal cystine crystals and visual acuity following treatment with topical cysteamine 0.55% eye drops in patients with nephropathic cystinosis.Photophobia, slit lamp assessment of corneal cystine crystals and visual acuity are recorded pretreatment, on each monthly visit up to 48 months.Patients had a baseline ophthalmic examination before initiation of topical cysteamine 0.55% eye drops and subsequent monthly follow up exams. The following parameters were recorded pretreatment, on each monthly visit and post treatment at last follow up visit: photophobia, slit lamp assessment of corneal cystine crystals and visual acuity. Photophobia was classified as grade 0 (none) for no photophobia, grade 1 (mild) for photophobia in bright light, grade 2 (moderate) for photophobia in room light and grade 3 (severe) for photophobia in dim light. Corneal cystine crystals were graded as Grade 0 = None, Grade 1 = 1-10 crystals/mm, Grade 2 = 11- 50 crystals/mm, Grade 3 = more than 50 crystals/mm. The level of cystine in the corneal layers was recorded and the location whether peripheral or central was also identified. Visual acuity was measured by Snellen chart at 20 feet with best distance correction.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026